OA11599A - Non-peptide GnRH agents, methods and intermediatesfor their preparation. - Google Patents

Non-peptide GnRH agents, methods and intermediatesfor their preparation. Download PDF

Info

Publication number
OA11599A
OA11599A OA1200100043A OA1200100043A OA11599A OA 11599 A OA11599 A OA 11599A OA 1200100043 A OA1200100043 A OA 1200100043A OA 1200100043 A OA1200100043 A OA 1200100043A OA 11599 A OA11599 A OA 11599A
Authority
OA
OAPI
Prior art keywords
compound
substituted
cycloalkyl
heterocycle
alkyl
Prior art date
Application number
OA1200100043A
Other languages
English (en)
Inventor
Mark Brian Anderson
Lance Christopher Christie
James Faust
Yufeng Hong
Haitao Li
David Robert Luthin
Genevieve Deguzman Paderes
Ved P Pathak
Eileen Valenzuela Tompkins
Haresh N Vazir
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of OA11599A publication Critical patent/OA11599A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
OA1200100043A 1998-08-20 1999-08-20 Non-peptide GnRH agents, methods and intermediatesfor their preparation. OA11599A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9752098P 1998-08-20 1998-08-20

Publications (1)

Publication Number Publication Date
OA11599A true OA11599A (en) 2004-08-23

Family

ID=22263796

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100043A OA11599A (en) 1998-08-20 1999-08-20 Non-peptide GnRH agents, methods and intermediatesfor their preparation.

Country Status (33)

Country Link
EP (1) EP1105120B1 (id)
JP (1) JP2002535244A (id)
KR (1) KR20010085402A (id)
CN (1) CN1379666A (id)
AP (1) AP2001002053A0 (id)
AT (1) ATE291423T1 (id)
AU (1) AU759310B2 (id)
BG (1) BG105362A (id)
BR (1) BR9913374A (id)
CA (1) CA2341346A1 (id)
CZ (1) CZ2001523A3 (id)
DE (1) DE69924387D1 (id)
EA (1) EA200100255A1 (id)
EE (1) EE200100102A (id)
ES (1) ES2237966T3 (id)
GE (1) GEP20043315B (id)
HR (1) HRP20010206A2 (id)
HU (1) HUP0103622A3 (id)
ID (1) ID29244A (id)
IL (1) IL141396A0 (id)
IS (1) IS5846A (id)
LT (1) LT4904B (id)
LV (1) LV12732B (id)
NO (1) NO20010309L (id)
NZ (1) NZ509252A (id)
OA (1) OA11599A (id)
PL (1) PL356984A1 (id)
SI (1) SI20746A (id)
SK (1) SK2262001A3 (id)
TR (1) TR200100631T2 (id)
WO (1) WO2000020358A2 (id)
YU (1) YU13701A (id)
ZA (1) ZA200100831B (id)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983991B1 (en) * 1992-04-22 2003-12-17 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
AU775123B2 (en) * 1999-03-24 2004-07-15 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
CO5370679A1 (es) * 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
CA2449843A1 (en) * 2001-06-06 2002-12-12 Eric T. Sun Non-peptide gnrh agents, pharmaceutical compositions and methods for their use, and processes for preparing them
CN100509797C (zh) * 2001-06-11 2009-07-08 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
GB0126292D0 (en) * 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
JP2005170790A (ja) * 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
US6521395B1 (en) * 2002-01-30 2003-02-18 Eastman Kodak Company Infrared couplers for incorporating and recovering metadata
AU2003202115A1 (en) * 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
MXPA04012566A (es) 2002-06-13 2005-04-19 Pfizer Agentes no peptidicos reguladores de la gnrh, composiciones farmaceuticas y procedimientos para su uso.
CA2507532A1 (en) * 2002-11-20 2004-06-03 Paradigm Therapeutics Ltd. Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone)
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
CN100451004C (zh) * 2003-03-31 2009-01-14 大正制药株式会社 嘧啶衍生物
JP2007525460A (ja) * 2003-04-25 2007-09-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ｃ−ｆｍｓキナーゼ阻害剤
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
US20050004133A1 (en) * 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
BRPI0412360A (pt) * 2003-07-09 2006-09-05 Paradigm Therapeutics Ltd compostos de organossilìcio e seu uso
CA2531511A1 (en) * 2003-07-10 2005-01-20 Paradigm Therapeutics Ltd. Silicon compounds and their use
US20050182061A1 (en) * 2003-10-02 2005-08-18 Jeremy Green Phthalimide compounds useful as protein kinase inhibitors
US20090291915A1 (en) * 2004-12-17 2009-11-26 Graham Andrew Showell Silicon Compounds and Their Use
US7569600B2 (en) 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
JP5118029B2 (ja) 2005-06-14 2013-01-16 タイゲン バイオテクノロジー カンパニー，リミテッド ピリミジン化合物
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
WO2007000582A1 (en) * 2005-06-28 2007-01-04 Takeda Cambridge Limited Heterocyclic non-peptide gnrh antagonists
WO2007019345A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
US20080070987A1 (en) * 2006-05-12 2008-03-20 Francesc Yraola Font Meta-xylylenediamine vanadate salts
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US8519137B2 (en) * 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
NZ585587A (en) * 2007-10-31 2012-04-27 Res Found Itsuu Lab Retinoid prodrug compound
EP2268635B1 (en) 2008-04-21 2015-06-10 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
UY31984A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
WO2010056847A2 (en) 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
SG187209A1 (en) 2010-08-05 2013-03-28 Amgen Inc Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
CN102050823A (zh) * 2010-10-27 2011-05-11 华东理工大学 新型光稳定剂-鸟嘌呤类似物的合成及表征
WO2012112567A1 (en) * 2011-02-15 2012-08-23 Georgetown University Small molecule inhibitors of agbl2
US9493451B2 (en) 2011-05-16 2016-11-15 Bionomics Limited Amine derivatives as potassium channel blockers
WO2013014204A2 (en) * 2011-07-26 2013-01-31 Sanofi 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
AU2012334804B2 (en) * 2011-11-07 2016-12-15 The University Of Queensland Modulators of C3a receptors
EP2908811B1 (en) * 2012-10-17 2020-12-09 Exonate Limited Compounds useful for treating ocular neovascularisation
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
WO2017070235A1 (en) * 2015-10-19 2017-04-27 Attenua, Inc. Antitussive compositions and methods
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499002A (en) * 1968-06-20 1970-03-03 Robins Co Inc A H 1-carbamoyl-3-aroylpyrrolidines
NL6913261A (id) * 1968-09-09 1970-03-11
US3932444A (en) * 1972-04-28 1976-01-13 E. I. Du Pont De Nemours & Co. 4-Imidazolylsulfonylimidazoles
US4013647A (en) * 1976-03-23 1977-03-22 American Home Products Corporation Morpholine containing tetrazole-5-carboxamide derivatives
GB1491776A (en) * 1976-09-08 1977-11-16 Pfizer Ltd Thiadiazoles
US4096153A (en) * 1977-01-21 1978-06-20 American Home Products Corporation Arylene-bis-tetrazole-5-carboxamides
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
JPH06509075A (ja) 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
EP0619814A1 (en) * 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
ATE243204T1 (de) * 1995-08-24 2003-07-15 Basf Ag Isoxazole- und isothiazole-5-carboxamid derivate, deren herstellung und deren verwendung als herbizide
NZ325060A (en) * 1995-12-14 2000-02-28 Merck & Co Inc Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
EP0901489A1 (en) * 1996-05-20 1999-03-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5878393A (en) * 1996-09-09 1999-03-02 Matsushita Electric Industrial Co., Ltd. High quality concatenative reading system

Also Published As

Publication number Publication date
HUP0103622A3 (en) 2003-01-28
SK2262001A3 (en) 2002-12-03
WO2000020358B1 (en) 2001-01-04
KR20010085402A (ko) 2001-09-07
LV12732A (en) 2001-10-20
EP1105120A2 (en) 2001-06-13
JP2002535244A (ja) 2002-10-22
LT2001024A (en) 2001-11-26
EE200100102A (et) 2002-06-17
BG105362A (en) 2001-12-31
ID29244A (id) 2001-08-16
CN1379666A (zh) 2002-11-13
WO2000020358A3 (en) 2000-11-16
EP1105120A4 (en) 2001-12-19
NZ509252A (en) 2004-05-28
LT4904B (lt) 2002-04-25
PL356984A1 (en) 2004-07-12
IS5846A (is) 2001-02-16
WO2000020358A2 (en) 2000-04-13
ATE291423T1 (de) 2005-04-15
AU2470900A (en) 2000-04-26
DE69924387D1 (de) 2005-04-28
LV12732B (en) 2002-03-20
SI20746A (sl) 2002-06-30
HUP0103622A2 (hu) 2002-04-29
IL141396A0 (en) 2002-03-10
ES2237966T3 (es) 2005-08-01
EP1105120B1 (en) 2005-03-23
HRP20010206A2 (en) 2004-02-29
GEP20043315B (en) 2004-02-10
CA2341346A1 (en) 2000-04-13
AP2001002053A0 (en) 2001-03-31
AU759310B2 (en) 2003-04-10
NO20010309L (no) 2001-04-11
BR9913374A (pt) 2001-05-15
ZA200100831B (en) 2002-08-22
EA200100255A1 (ru) 2002-02-28
CZ2001523A3 (cs) 2002-05-15
NO20010309D0 (no) 2001-01-19
YU13701A (sh) 2005-06-10
TR200100631T2 (tr) 2002-08-21

Similar Documents

Publication Publication Date Title
OA11599A (en) Non-peptide GnRH agents, methods and intermediatesfor their preparation.
CA3004173C (en) 7-(thiazol-5-yl)pyrrolopyrimidine compound as tlr7 agonist
TWI485150B (zh) 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用
US7101878B1 (en) Non-peptide GNRH agents, methods and intermediates for their preparation
CA2807460C (en) Heterocyclic compound and use thereof
EP1334972B1 (en) Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH)
IL180757A (en) Imidazo[4,5-d] pyrimidines, compositions comprising them and uses thereof for the preparation of medicaments
WO2007042669A2 (fr) DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl
KR20200055126A (ko) Ａ2ａ수용체 억제제로서의 축합 고리 유도체
US9045462B2 (en) Synthesis of an antiviral compound
FR2891825A1 (fr) Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique
US20040010033A1 (en) Non-peptide GnRH agents, methods and intermediates for their preparation
CN110013483B (zh) 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途
WO2003106446A1 (en) Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
CN109503518B (zh) 一种取代的双芳香基酰胺化合物及其制备方法和应用
CN102212032B (zh) 一种5-羟基喹诺酮类衍生物及其制备方法和用途
CN112204035A (zh) 取代的3,4,12,12а-四氢-1Н-[1,4]噁嗪并[3,4-c]吡啶并[2,1-f][1,2,4]三嗪-6,8-二酮、其药物组合物、生产方法及用途
TW202345801A (zh) 具有病毒增殖抑制活性之尿嘧啶衍生物及含有其等之醫藥組合物
WO2023055580A1 (en) Benzylthiophene derivatives
KR101480759B1 (ko) 아자인돌 유도체 화합물, 이를 포함하는 Ｔｒｋ 저해제 조성물 및 Ｔｒｋ와 관련된 질환의 예방 및 치료용 약학 조성물
KR101568484B1 (ko) 벤조텔루로펜 유도체